Loading organizations...
§ Private Profile · Cambridge, MA, USA
Torus Biosystems is a technology company.
Torus Biosystems develops point-of-care diagnostic tools for infectious diseases. The platform offers rapid, quantitative, multiplexed identification of microbial pathogens and host immune-response markers. Utilizing DNA nanotechnology, specifically toehold chemistry, it integrates microarray and qPCR to deliver diagnostic results at the patient's bedside in under 30 minutes.
The company launched in August 2020 from Harvard’s Wyss Institute, commercializing DNA nanotechnology developed by cofounders Peng Yin and David Zhang. Dr. Yin, a Wyss Core Faculty member and Harvard Medical School Professor, pioneered toehold probe technology. Dr. Zhang, a Wyss alumnus and Rice University Associate Professor, also cofounded Torus; Shawn Marcell serves as CEO.
Torus Biosystems’ diagnostic solutions are designed for clinicians guiding critical therapeutic decisions. The company aims to overcome conventional assay limitations by providing rapid, comprehensive, actionable diagnostic insights at the point of care. This enables precision medicine, significantly improving patient outcomes in challenging infectious diseases.
Torus Biosystems has raised $25.0M across 1 funding round.
Torus Biosystems has raised $25.0M in total across 1 funding round.
Torus Biosystems has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2021 | $25M Series A | Northpond Ventures | 6 Dimensions Capital, ARCH Venture Partners, David R. Walt | Announced |
Torus Biosystems has raised $25.0M in total across 1 funding round.
Torus Biosystems's investors include Northpond Ventures, 6 Dimensions Capital, ARCH Venture Partners, David R. Walt.
Torus Biosystems is a biotech company developing rapid, point-of-care molecular diagnostics for infectious diseases using proprietary DNA/RNA detection technology.[1][2][3] Its flagship Synestia System integrates microarray and qPCR technologies to deliver sample-to-insight results from urine, swab, or blood in under 30 minutes, enabling early pathogen identification, personalized treatment, reduced antibiotic overuse, and combating antimicrobial resistance.[1][3] The company serves healthcare settings like hospital outpatient departments, emergency rooms, and long-term care facilities, with scalable solutions for research and medical innovation.[1][3] Founded as a spinout from Harvard's Wyss Institute, it raised $25M in Series A funding in May 2021 from investors including Northpond Ventures, positioning it for growth in diagnostics.[2][3]
Torus Biosystems emerged from groundbreaking research at the Wyss Institute for Biologically Inspired Engineering at Harvard University, spinning out in 2019-2020 to commercialize DNA nanotechnology for molecular diagnostics.[1][2][4] The core technology stems from work by Peng Yin, PhD, Wyss Core Faculty and Professor of Systems Biology at Harvard Medical School, and David Zhang, PhD, Wyss Alumnus and Associate Professor of Bioengineering at Rice University.[2] Shawn Marcell serves as Chairman & CEO, bringing experience from ReadCoor, Inc. and Excel Venture Management.[2] Early momentum included securing licensing from Harvard and initial funding, with the company basing operations in Cambridge/Medford, Massachusetts, to translate academic innovation into clinical tools amid rising needs for fast infectious disease testing.[1][2][4]
Torus rides the point-of-care diagnostics wave, accelerated by pandemics like COVID-19 and ongoing antimicrobial resistance crises, where delayed testing leads to misuse of antibiotics and poor outcomes.[1][3] Timing aligns with market forces favoring decentralized, rapid testing: global diagnostics demand surges (projected multi-billion market), regulatory pushes for faster POC tools, and biotech spinouts bridging academia to clinics.[2][4] By influencing ecosystems through Wyss/Harvard networks and investor backing like Northpond Ventures, Torus advances precision medicine, potentially shaping standards for infectious disease management in overburdened healthcare systems.[1][2]
Torus is poised for expansion with its validated Synestia platform, likely pursuing FDA approvals, broader clinical adoption, and new assays for emerging pathogens.[1][3] Trends like AI-enhanced diagnostics and global health threats will propel growth, evolving its role from innovator to ecosystem leader in combating resistance. As a Wyss spinout scaling biologically inspired tech, expect partnerships and follow-on funding to amplify impact—tying back to its mission of transforming patient outcomes through speed and precision.[2][4]